Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k

Published 13/08/2025, 22:04
Dawn Halkuff sells Xeris Biopharma (XERS) shares worth $309k

Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma Holdings, Inc. NASDAQ:XERS on August 12, 2025. The transaction comes as the stock trades near its 52-week high of $7.61, having surged over 100% in the past six months. The shares were sold at a weighted average price of $7.2759, resulting in a total transaction value of $309,225.

The sales were executed in multiple transactions with prices ranging from $7.190 to $7.450. Following the transaction, Halkuff directly owns 115,000 shares of Xeris Biopharma.

Halkuff also indirectly owns 5,410 shares through the DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017.

In other recent news, Xeris Pharmaceuticals reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company posted an earnings per share (EPS) of -0.01, beating the forecasted -0.03. Additionally, Xeris achieved a revenue of $71.5 million, exceeding projections by 11.85%. These results highlight a strong performance for the quarter. In analyst coverage, H.C. Wainwright has assumed coverage of Xeris Pharmaceuticals with a Buy rating and set a price target of $10.00. The firm noted that Xeris stock has risen significantly, with a 108% increase year to date in 2025. These developments suggest a positive outlook from analysts and strong financial performance from the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.